These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 19664676)
1. Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine. Ikenouchi-Sugita A; Yoshimura R; Hori H; Umene-Nakano W; Ueda N; Nakamura J Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1451-3. PubMed ID: 19664676 [TBL] [Abstract][Full Text] [Related]
2. Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression. Morishita S; Arita S Hum Psychopharmacol; 2003 Aug; 18(6):479-82. PubMed ID: 12923828 [TBL] [Abstract][Full Text] [Related]
3. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Chrapko WE; Jurasz P; Radomski MW; Lara N; Archer SL; Le Mellédo JM Biol Psychiatry; 2004 Jul; 56(2):129-34. PubMed ID: 15231445 [TBL] [Abstract][Full Text] [Related]
4. Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression. Lee MS; Ham BJ; Kee BS; Kim JB; Yeon BK; Oh KS; Oh BH; Lee C; Jung HY; Chee IS; Choe BM; Paik IH Curr Med Res Opin; 2005 Sep; 21(9):1369-75. PubMed ID: 16197655 [TBL] [Abstract][Full Text] [Related]
5. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. Selley ML J Affect Disord; 2004 Jun; 80(2-3):249-56. PubMed ID: 15207938 [TBL] [Abstract][Full Text] [Related]
6. Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Baldwin D; Moreno RA; Briley M Hum Psychopharmacol; 2008 Aug; 23(6):527-32. PubMed ID: 18536065 [TBL] [Abstract][Full Text] [Related]
7. No predictors of antidepressant patient response to milnacipran were obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale in Japanese patients with major depressive disorders. Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N Psychiatry Clin Neurosci; 2008 Apr; 62(2):197-202. PubMed ID: 18412843 [TBL] [Abstract][Full Text] [Related]
8. Treatment with paroxetine, but not amitriptyline, lowers levels of lipoprotein(a) in patients with major depression. Paslakis G; Kopf D; Westphal S; Gilles M; Lederbogen F; Hamann B; Heuser I; Deuschle M J Psychopharmacol; 2011 Oct; 25(10):1344-6. PubMed ID: 20952454 [TBL] [Abstract][Full Text] [Related]
9. A comparative study of milnacipran and imipramine in the treatment of major depressive disorder. Lopez-Ibor JJ; Conesa A; Curr Med Res Opin; 2004 Jun; 20(6):855-60. PubMed ID: 15200743 [TBL] [Abstract][Full Text] [Related]
10. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385 [TBL] [Abstract][Full Text] [Related]
11. Serum brain-derived neurotrophic factor levels in patients with major depression: effects of antidepressants. Huang TL; Lee CT; Liu YL J Psychiatr Res; 2008 Jun; 42(7):521-5. PubMed ID: 17585940 [TBL] [Abstract][Full Text] [Related]
12. Effect of pindolol and milnacipran versus milnacipran and placebo on plasma prolactin and adrenocorticotrophic hormone in depressed subjects. Isaac MB; Isaac MT Hum Psychopharmacol; 2003 Oct; 18(7):569-74. PubMed ID: 14533141 [TBL] [Abstract][Full Text] [Related]
13. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. Akiskal HS; Benazzi F; Perugi G; Rihmer Z J Affect Disord; 2005 Apr; 85(3):245-58. PubMed ID: 15780694 [TBL] [Abstract][Full Text] [Related]
14. Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients. Chrapko W; Jurasz P; Radomski MW; Archer SL; Newman SC; Baker G; Lara N; Le Mellédo JM Neuropsychopharmacology; 2006 Jun; 31(6):1286-93. PubMed ID: 16319917 [TBL] [Abstract][Full Text] [Related]
15. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961 [TBL] [Abstract][Full Text] [Related]
16. Paroxetine-induced increase in metabolic end products of nitric oxide. Lara N; Archer SL; Baker GB; Le Mellédo JM J Clin Psychopharmacol; 2003 Aug; 23(4):408-12. PubMed ID: 12920419 [TBL] [Abstract][Full Text] [Related]
17. [Antidepressants consumption in the global population in France]. Olié JP; Elomari F; Spadone C; Lépine JP Encephale; 2002; 28(5 Pt 1):411-7. PubMed ID: 12386542 [TBL] [Abstract][Full Text] [Related]
18. Clinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic. Nakao M; Takeuchi T; Nomura K; Teramoto T; Yano E Psychiatry Clin Neurosci; 2006 Oct; 60(5):605-10. PubMed ID: 16958945 [TBL] [Abstract][Full Text] [Related]
19. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072 [TBL] [Abstract][Full Text] [Related]
20. Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients. Naito S; Sato K; Yoshida K; Higuchi H; Takahashi H; Kamata M; Ito K; Ohkubo T; Shimizu T Psychiatry Clin Neurosci; 2007 Aug; 61(4):421-7. PubMed ID: 17610668 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]